OXFORD, United Kingdom, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and C. difficile infection (‘CDI’), today reports its financial results for the third quarter ended 31 October 2015.
Mr Glyn Edwards, Chief Executive Officer of Summit commented: “We have recently announced positive clinical trial results for both our lead programmes in DMD and CDI, enabling us to advance these promising candidates to the next stage of clinical development. In DMD, our lead utrophin modulator, SMT C1100, is poised to enter a Phase 2 proof of concept trial after demonstrating the ability to achieve exposure levels in patients that we believe may be able to sustain utrophin production and result in clinical benefit. Utrophin modulation has significant promise as a disease-modifying therapy for all patients living with DMD.
Mr Glyn Edwards, Chief Executive Officer of Summit commented: “We have recently announced positive clinical trial results for both our lead programmes in DMD and CDI, enabling us to advance these promising candidates to the next stage of clinical development. In DMD, our lead utrophin modulator, SMT C1100, is poised to enter a Phase 2 proof of concept trial after demonstrating the ability to achieve exposure levels in patients that we believe may be able to sustain utrophin production and result in clinical benefit. Utrophin modulation has significant promise as a disease-modifying therapy for all patients living with DMD.
